Highbridge Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Highbridge Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-68,097	Closed	-$572K	–	1249
2017 Q1	$572K	Buy	+68,097	New	+$474K	0.01%	838
2016 Q4	–	Sell	-176,962	Closed	-$780K	–	1260
2016 Q3	$780K	Buy	176,962 +44,674	+34%	+$178K	0.01%	635
2016 Q2	$376K	Buy	132,288 +111,755	+544%	+$347K	0.01%	963
2016 Q1	$58K	Buy	+20,533	New	+$91K	﹤0.01%	1423
2015 Q3	–	Sell	-137,042	Closed	-$2.05M	–	1531
2015 Q2	$2.05M	Buy	137,042 +99,525	+265%	+$1.13M	0.03%	518
2015 Q1	$339K	Buy	+37,517	New	+$388K	﹤0.01%	1079
2014 Q4	–	Sell	-32,797	Closed	-$321K	–	1169
2014 Q3	$321K	Sell	32,797 -49,749	-60%	-$610K	﹤0.01%	981
2014 Q2	$1.05M	Buy	+82,546	New	+$803K	0.01%	554

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Highbridge Capital Management's BCRX Position: Q2 2017 in Review

Highbridge Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2017, closing a stake of 68,097 shares — an estimated $572K sold.

Highbridge Capital Management first reported a position in BCRX in Q2 2014 and held it in 8 quarters. The position peaked at $2.05M in Q2 2015. 115 funds tracked by Wall St. Rank hold BCRX as of Q2 2017.

Highbridge Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Highbridge Capital Management sold 68,097 BioCryst Pharmaceuticals shares in Q2 2017, an estimated $572K.
Highbridge Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 8 quarters.
Highbridge Capital Management's BioCryst Pharmaceuticals position peaked at $2.05M in Q2 2015.
115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.